SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

PraziTape 50 mg Film-Coated Tablets for Dogs and Cats

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active substances:
Praziquantel 50.0 mg

Excipients:

Qualitative composition of excipients and other constituents	**Quantitative composition if that information is essential for proper administration of the veterinary medicinal product**
Core	
Cellulose, Microcrystalline	
Lactose Monohydrate	
Croscarmellose Sodium	
Maize starch	
Povidone K30	
Sodium lauryl sulphate	
Silica, Colloidal Anhydrous	
Magnesium Stearate	
Coat	
Opadry II White	16.25 mg
Grilled meat flavour	

A white to off white film-coated tablet with a breakline on one side.

3. CLINICAL INFORMATION

3.1 Target species

Dogs and cats.

3.2 Indications for use for each target species

In dogs and cats: treatment of adult tapeworms (immature and mature forms) of the following species:
Echinococcus granulosus
Echinococcus multilocularis
Taenia ovis
Taenia pisiformis
Taenia multiceps
Taenia hydatigena

Taenia taeniaeformis
Dipylidium caninum

3.3 Contraindications

Do not use in dogs or cats weighing less than 2.5 kg.
Do not administer to unweaned puppies and kittens.
Do not use in animals with known hypersensitivity to the active substances or to any of the excipients.
Do not use simultaneously with other deworming products without veterinary advice.

3.4 Special warnings

In order to develop an effective worm control programme local epidemiological information and the risk of exposure of the animal should be taken into account, and it is recommended to seek professional advice, e.g. from a veterinary surgeon or Suitably Qualified Person (registered animal medicines advisor).

It is recommended to treat all the animals living in the same household concomitantly.

Fleas serve as intermediate hosts for one common type of tapeworm-*Dipylidium caninum*. To avoid reinfection with this parasite, flea control of the animal and its housing should be carried out at the same time. Unless flea control is complete an infected flea population may survive: i.e. re-treatment of the animal may be necessary.

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy.

3.5 Special precautions for use

Special precautions for safe use in the target species:
Any part used tablets should be discarded.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
This veterinary medicinal product may be harmful when ingested, particularly for children.
Avoid accidental ingestion.
The product should be stored in a safe place out of the sight and reach of children.
Any unused part tablets should be discarded.
In the case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after administering the veterinary medicinal product

Special precautions for the protection of the environment:
See section 5.5.

Other precautions:
Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (WOAH), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority (e. g. experts or institutes of parasitology).

If the animal has visited areas where *Echinococcus* spp. are prevalent, a veterinary surgeon should be consulted.

3.6 Adverse events

Dogs and cats:

Unknown	Vomiting

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The product can be used during pregnancy and lactation.

3.8 Interaction with other medicinal products and other forms of interaction

Plasma concentrations of praziquantel may be decreased by concomitant administration with drugs that increase the activity of cytochrome P-450 enzymes (e.g. dexamethasone, phenobarbital).

3.9 Administration routes and dosage

Oral use.

Dosage:
The minimum recommended dose rate is 5 mg/kg body weight. This corresponds to 1 tablet per 10 kg body weight.

To ensure a correct dosage, body weight should be determined as accurately as possible. Underdosing could result in ineffective use and may favour resistance development.

Dogs:

Weight	**Number of Tablets**
Equal to/greater than 2.5 up to 5.0 kg	½ tablet
Greater than 5.0 up to 10.0 kg	1 tablet
Greater than 10.0 up to 20.0 kg	2 tablets
Greater than 20.0 up to 30.0 kg	3 tablets
Greater than 30.0 kg	*pro rata*

Cats:

Weight	**Number of Tablets**
Equal to/greater than 2.5 up to 5.0 kg	½ tablet
Greater than 5.0 up to 10.0 kg	1 tablet
Greater than 10.0 kg	*pro rata*

The tablets are administered as a single dose orally, by opening the animal's mouth and pushing the tablet over the back of the tongue so that it cannot be rejected. Alternatively, a tablet can be wrapped in a piece of meat or butter and offered to the animal or crushed and mixed with the food.

The need for and frequency of re-treatment should be based on professional advice and should take into account individual risk factors (the local epidemiological situation and the animal's lifestyle).

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Praziquantel is well tolerated with a wide safety margin. Doses higher than recommended may cause vomiting.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QP52AA01

4.2 Pharmacodynamics

Praziquantel is a pyrazinoisoquinoline derivative effective against the cestodes (tapeworms) *Echinococcus granulosus*, *E. multilocularis, Taenia ovis, T. pisiformis, T. multiceps, T. hydatigena, T. taeniaeformis,* and *Dipylidium caninum.* Praziquantel is rapidly adsorbed via the surface of the parasites and acts primarily by changing the Ca++ permeability of the parasite membranes. This results in severe damage to the parasite integument, contraction and paralysis, disruption of metabolism and finally leads to the death of the parasite.

4.3 Pharmacokinetics

Praziquantel is rapidly absorbed by the animal and metabolised by the liver. It is excreted, entirely as metabolites, in the urine and faeces

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

Shelf life after first opening the immediate packaging: use immediately.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

Blister packs made up of a cold form laminate of OPA/ALU/PVC of thickness 25µm/47µm/60µm with a 20µm hard tempered aluminium foil.
Available pack sizes:
Cardboard box containing 1 tablet. (1 blister strip of 1)
Cardboard box containing 10 tablets. (1 blister strip of 10)
Cardboard box containing 20 tablets. (2 blister strips of 10)
Cardboard box containing 24 tablets. (3 blister strips of 8)
Cardboard box containing 48 tablets. (6 blister strips of 8)
Cardboard box containing 100 tablets. (10 blister strips of 10)
Cardboard box containing 104 tablets. (13 blister strips of 8)

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd

7. MARKETING AUTHORISATION NUMBERS

UK(GB) Vm 08749/5058
UK(NI) Vm 08749/3021

8. DATE OF FIRST AUTHORISATION

25 August 2026

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

August 2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product not subject to prescription.
Find more product information by searching for the 'Product Information Database' or "PID" on www.gov.uk

Gavin Hall
Approved: 07 October 2026